At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Amniotic Fluid Eye Drops (AFED) +1 morebiological
Likely dose
Amniotic Fluid Eye Drops (AFED) 0.25 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blinded, Placebo-Controlled Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)
In Brief
A Phase 2 clinical trial evaluating Amniotic Fluid Eye Drops (AFED) and Saline Solution for Ocular Graft Versus Host Disease. Completed, enrolled 15 participants across 1 site.
Detailed Summary
A Randomized, Double-blinded, Placebo-Controlled Study for the Treatment of Ocular Chronic Graft Verses Host Disease with Processed Amniotic Fluid (pAF) Drops.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Graft Versus Host Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2019
Primary CompletionDec 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedOct 2, 2017
Enrollment StartDec 20, 2019
Primary CompletionDec 16, 2022
Study CompletionFeb 24, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.8 years ago
Interventions
Amniotic Fluid Eye Drops (AFED)biological
One drop (0.25 mL) in one eye twice daily for up to 3 months
Saline Solutionother
One drop (0.25 mL) in the other eye twice daily for up to 3 months